Results 31 to 40 of about 80,877 (282)
Preventive Medicine Reports, 2019 The rate of opioid misuse and overdose continues to increase in rural areas of the U.S. In response, access to naloxone hydrochloride (“naloxone”), an opioid antagonist used to reverse opioid overdose, has increased among both first responders and ...
Tess M. Kilwein +3 more
doaj +1 more source
Harm Reduction Journal, 2022 Background Expanding availability to naloxone is a core harm reduction strategy in efforts to address the opioid epidemic. In the US, state-level legislation is a prominent mechanism to expand naloxone availability through various venues, such as ...
Sean Grant, Rosanna Smart
doaj +1 more source
Overdose Education and Naloxone Distribution Within Syringe Service Programs — United States, 2019
MMWR. Morbidity and mortality weekly report, 2020 Syringe service programs (SSPs), which provide access to sterile syringes and other injection equipment and their safe disposal after use,* represent a highly successful human immunodeficiency virus (HIV) prevention intervention. SSPs are associated with
B. Lambdin +6 more
semanticscholar +1 more source
Prehospital naloxone administration – what influences choice of dose and route of administration?
BMC Emergency Medicine, 2020 Background Amidst the ongoing opioid crisis there are debates regarding the optimal route of administration and dosages of naloxone. This applies both for lay people administration and emergency medical services, and in the development of new naloxone ...
Ida Tylleskar +6 more
doaj +1 more source
Addiction, 2020 Background and Aims Naloxone access laws (NALs) have been suggested to be an important strategy to reduce opioid-related harm. We describe the evolution of NALs across states and over time and review existing evidence of their overall association with ...
Rosanna Smart, Bryce Pardo, C. Davis
semanticscholar +1 more source
Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study
Harm Reduction Journal, 2006 Background Drug-induced and drug-related deaths have been increasing for the past decade throughout the US. In NYC, drug overdose accounts for nearly 900 deaths per year, a figure that exceeds the number of deaths each year from homicide.
Galea Sandro +3 more
doaj +1 more source
Legal gems: Supply of S3 naloxone [PDF]
, 2017 In February 2016, naloxone 400 mcg/mL was rescheduled for supply as a Schedule 3 (S3; Pharmacist Only) medication for the treatment of opioid overdose. For all other purposes, naloxone remains a Schedule 4 (S4; Prescription Only) medication.
Dickfos, Steven T +2 more
core +1 more source
Effects of pharmacist-driven protocol on naloxone prescribing rates in two primary care clinics
Preventive Medicine Reports, 2023 The Centers for Disease Control and Prevention (CDC) Guidelines for Prescribing Opioids for Chronic Pain recommend co-prescribing naloxone as a harm reduction strategy when there is an increased risk of opioid overdose.
Ashley Daffron +3 more
doaj +1 more source
Naloxone induced pulmonary edema [PDF]
, 2021 Naloxone-induced noncardiogenic pulmonary edema is a rare but reported entity that can occur following naloxone use in the reversal of opioid overdose.
Ramez Alyacoub +4 more
core +1 more source
PLoS ONE, 2020 IntroductionOverdose is a leading cause of death in the United States, especially among people who inject drugs (PWID). Improving naloxone access and carrying among PWID may offset recent increases in overdose mortality associated with the influx of ...
Megan Buresh +5 more
doaj +1 more source